SpyGlass Pharma BIM-IOL shows 37% IOP cut at four-year mark

Four-year first-in-human data show sustained intraocular pressure reduction and 86% of glaucoma patients remaining drop-free after cataract surgery.

The Biotech Times Editorial Team By The Biotech Times Editorial Team AI level 2 of 5
AI level 2 of 5: drafted by our AI editorial assistant from the company's announcement; fact-checked, edited and signed off by Mark Walker, Editorial Director. What the levels mean
Fine surgical tweezers hold a transparent circular lens above a sterile metal instrument tray in a brightly lit operating room.

SpyGlass Pharma has released four-year interim data from its first-in-human trial of the Bimatoprost Drug Pad-IOL System, a sustained-release implant designed to control intraocular pressure in patients with open angle glaucoma or ocular hypertension who are undergoing routine cataract surgery. The Irvine, California company said the results show a 37% mean reduction in IOP across all three dose groups, from 25.1 mmHg at baseline to 15.9 mmHg at the 48-month timepoint in 21 evaluable patients.

The headline figures are striking for a first-in-human dataset of this size. Eighty-six per cent of patients remained off all topical IOP-lowering drops, and 90% maintained best-corrected distance visual acuity of 20/25 or better. No product-related adverse events were reported at four years. Two of the original 23 patients left the trial before the 36-month visit, one due to relocation and one following a cancer diagnosis unrelated to the device.

Clinical design and regulatory path

The single-centre prospective trial assigned patients 1:1:1 across 75 mcg, 150 mcg and 300 mcg dose groups, and the BIM-IOL System in this cohort is designed to deliver bimatoprost for up to seven years; follow-up is scheduled to continue through 2029. The Phase 3 programme uses a modified version of the implant, configured to deliver bimatoprost for three years, and enrolment is ongoing. SpyGlass Pharma has said it plans to pursue a 505(b)(2) New Drug Application pathway, which allows applicants to rely in part on existing FDA data for the active ingredient. Bimatoprost was approved by the FDA as a topical prostaglandin analogue in 2001, a fact that meaningfully de-risks the pharmacology argument for the NDA submission.

Paul Yoo, senior vice president of clinical development, said the four-year profile "establishes a new benchmark for durable, drop-free disease control" in this setting. Chief executive Patrick Mooney framed the unmet need as approximately one million cataract procedures performed annually in the United States in patients with concurrent glaucoma.

Market context

The sustained-release ophthalmic space has attracted growing interest from device and pharma players as poor adherence to daily topical therapy remains one of the most stubborn problems in glaucoma management. Alcon's iDose TR, a travoprost-releasing implant, received FDA approval in late 2023 as a standalone procedure rather than a cataract surgery adjunct, which means BIM-IOL, if approved, would occupy a differentiated niche by addressing both conditions in a single operative episode. Separately, Glaukos has been active in sustained-release approaches to complement its iStent franchise.

The limitation of SpyGlass Pharma's current dataset is its size: 21 patients across three dose groups is a small cohort, and the absence of a randomised control arm in the FIH study means the IOP reduction figures cannot be compared directly against a vehicle or standard-of-care control. The Phase 3 results, which will carry that comparative rigour, will be the definitive test of whether the four-year trend holds at scale. Investors will be watching the enrolment trajectory and any interim safety signals from Phase 3 as the primary near-term value catalysts.

Sector

Topic

Geography